Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Medicines Q&As Q&A 24.7 What is the most appropriate antidepressant to use in people with epilepsy? Prepared by UK Medicines Information (UKMi) pharmacists for NHS healthcare professionals Before using this Q&A, read the disclaimer at https://www.sps.nhs.uk/articles/about-ukmi-medicines-qas/ Published: December 2016 Summary The first consideration should always be to check the patients’ anticonvulsant regimen for potential drug-induced depression. It may be that the patient would benefit from changing the anticonvulsant to another agent with a more favourable effect on mood rather than adding in an antidepressant. The risk of seizures with most antidepressants is low, but is probably not zero for any of them, and patients should be made aware of this when prescribing. The risk of seizures increases with increasing doses. Selective Serotonin Reuptake Inhibitors (SSRIs) are considered the first line antidepressant option in patients with epilepsy. Sertraline may be considered the better option due to safety data and reduced interaction potential with the anticonvulsants. Fluoxetine is not the best choice due to its long half-life, a possibly greater incidence of seizures and an increased risk of drug interactions. Moclobemide is a good alternative, as it has a low incidence of seizures but due to limited data it should be reserved as a second choice to SSRIs. Tricyclic antidepressants (TCAs) should be used cautiously in patients with epilepsy and reserved for patients who poorly respond to or are intolerant of other antidepressants. Where a TCA is needed, doxepin is possibly of lowest risk and therefore the agent of choice within this group. Clinicians should be aware of the possibility of interactions between antidepressants and anticonvulsants and should monitor carefully patients with epilepsy who are prescribed antidepressants. Introducing the antidepressant gradually, starting with a low dose, and not exceeding the maximum recommended doses may reduce the risk of a seizure. If seizures occur or if the incidence of seizures increases, the antidepressant should be discontinued. Detailed information regarding drug interactions has not been included in this Q&A: pharmacokinetic and pharmacodynamic drug interactions between antidepressants and antiepileptic drugs must be checked prior to prescribing. Background Depression is the most common co-morbidity in people with epilepsy (PWE) compared with the general population (1;2). Rates vary from 3-9% in patients with well-controlled epilepsy to much higher (20-55%) in those with recurrent seizures and those treated at tertiary referral centres (1;3;4). A population-based study estimated a lifetime prevalence of 17.4% in those with epilepsy compared to 10.7% in those without epilepsy (3). The presence of depression has been associated with poorer seizure control and has a greater negative impact on quality of life than the number of prescribed antidepressants or seizure frequency (5). A higher suicide rate than the general population has also been documented for PWE (6). The association between epilepsy and depression may be explained in part by serotonin; depletion of serotonin increases the risk of both depression and epilepsy (5;7). Abnormalities in other neurotransmitters such as noradrenaline, dopamine, and GABA are also seen in both conditions (3;5). Available through NICE Evidence Search at www.evidence.nhs.uk 1 Medicines Q&As Depressive symptoms present in a number of ways. Peri-ictal depression is relative to seizure activity, is short-lasting and does not require treatment with antidepressants; this should be treated by optimising anticonvulsant therapy (3;7). Peri-ictal depression can be divided into three types. Preictal (before a seizure) depressive symptoms manifest hours to days prior to a seizure. Ictal depression occurs minutes before a complex partial seizure. Post-ictal depression is characterised by a depressed mood developing in most cases hours to days after a seizure (1;3). Inter-ictal depression presents as chronic depression; this is not related to seizure activity and is likely to require treatment with antidepressants (1;3;7). PWE are three times more likely to be prescribed an antidepressant than the general population and two times more likely to report suicidal thoughts (8). Many antidepressants may lower the seizure threshold, but there is also evidence that when used within their therapeutic dosage range, the risk of seizure activity is low (1). Guidelines suggest that Selective Serotonin Reuptake Inhibitors (SSRIs) are an appropriate first-line choice for treating depression in PWE (4;9). What data supports this choice, or the choice of antidepressants from other drug classes? Answer Use of antiepileptic drugs (AEDs) with mood stabilising properties may be appropriate for selected individuals with mild depressive symptoms (3). For example, gabapentin, carbamazepine, oxcarbazepine, valproate, and lamotrigine improve depressive symptoms in epileptic patients (1;2;10), whereas phenobarbitone, vigabatrin, primidone, topiramate and tiagabine have negative psychotropic properties and have been associated with depression (1). There is a lack of information regarding the safety of antidepressants in PWE (9) and the choice is a common clinical dilemma. A recent Cochrane review, for example, concluded there is no high quality evidence to inform the choice of antidepressant drug in treating depression in PWE (11). Some antidepressants, especially the tricyclic antidepressants (TCAs), are well known to lower the seizure threshold but the risk is dose related (7). There is no large study comparing seizure frequency in PWE who take antidepressants with those who do not (12). With few exceptions, all antidepressants are associated with seizures in overdose; SSRIs are less likely to cause seizures in overdose than TCAs (13). However, the perceived risks are often overestimated and rarely outweigh the risk of leaving depression untreated (8). Treatment of depression in PWE can improve their quality of life and reduce their risk of suicide (5). It is important to check the anticonvulsant regimen of an epileptic patient with depression for potential drug-induced depression before considering adding an antidepressant. Selective Serotonin Reuptake Inhibitors (SSRIs) In general, the SSRIs are considered the first-line choice in patients with stable epilepsy because they have a low pro-convulsive effect and are associated with a lower incidence of seizures when compared with TCAs (1-4;7;8;14). Treatment should be initiated with a low dose and increased gradually, as necessary (9). If seizures occur, or if the incidence of seizures increases, the antidepressant should be discontinued (15-20). The risk of seizures at therapeutic doses of SSRIs is between 0-0.3%, compared with 0.4 to 1-2% with TCAs (13), though this varies between individual agents. Studies of short and long-term SSRI treatment (1 month to around 15 months), suggest there is no worsening in seizure frequency and in some patients improvement in seizure outcomes are seen. It should also be noted that in some patients, seizure frequency worsened but could be controlled by either increasing the dose of antiepileptic drug, or discontinuing the antidepressant (2). There is a lack of double-blind, randomised controlled trials in large patient populations; most have been small studies in highly selected patients (2). Drug interactions with SSRIs must be taken into consideration: escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline inhibit cytochrome P450 enzymes to varying degrees and may increase the plasma levels of AEDs (5;15-20). Available through NICE Evidence Search at www.evidence.nhs.uk 2 Medicines Q&As Fluoxetine is the most studied SSRI and has a probable seizure incidence of 0.2% (14;21). Fluoxetine should be avoided in patients with unstable seizure disorders and patients with controlled epilepsy should be monitored (17). It is a potent CYP2D6 enzyme inhibitor and can cause changes in blood levels of phenytoin such that cases of phenytoin toxicity have been reported (7;17;22). The long half-life of fluoxetine should be taken into consideration when starting or stopping treatment (17). Pre-marketing studies and a retrospective survey of prescriptions (n=10,401) suggested the incidence of seizures with fluvoxamine to be 0.2% in the general population (13;23). One small-scale study (n=28) reported that fluvoxamine was not proconvulsant at doses ranging from 50 to 200mg, when given to depressed PWE (24), however there have been case reports of seizures following therapeutic doses of fluvoxamine in patients with and without a previous history of seizures (25;26). Fluvoxamine should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored (18). Fluvoxamine inhibits CYP1A2 and CYP2C19, and to a lesser extent, CYP2C9, CYP2D6 and CYP3A4; co-administration with antiepileptics metabolised by these isoenzymes, such as phenytoin and carbamazepine, may lead to higher plasma levels of the AED and dose adjustments may be necessary (18). Paroxetine appears to have a minimal potential for producing seizures at therapeutic doses (14) and reviews suggest paroxetine has a seizure incidence of less than 0.1% (21). Paroxetine is a potent inhibitor of several CYP enzyme systems and concurrent use with AEDs may require dosage adjustments (7;22). Paroxetine dose adjustment may also be necessary if an enzyme inducer (such as carbamazepine, phenytoin or phenobarbitone) is initiated or discontinued and it should be used with caution (19). Citalopram and escitalopram have not been reported to have a proconvulsive effect in postmarketing data except in overdose (7;14). In an open label study citalopram 20mg/day for 4 months was associated with an improvement in depressive symptoms and a reduction in seizure frequency (from 1.31 per month to 0.82, p<0.005) in 39 patients who had epilepsy and depression (27). A study of 43 patients with epilepsy showed citalopram (average dose 22.6mg) to be an effective antidepressant without affecting monthly seizure frequency or causing de novo generalised tonicclonic seizures when used for 2 months (28). A third study also showed citalopram (mean dose 24mg) to be an effective treatment without causing an increase in seizure frequency in 33 patients with temporal lobe epilepsy, when used for up to 30 weeks (29). Citalopram is a weak inhibitor of hepatic CYP enzyme systems and there is a lack of documented interactions with the anticonvulsant agents (7). However, due to the potential for all SSRIs to cause seizures, and citalopram’s proconvulsive effect in overdose (7), it should be used with caution in patients with controlled epilepsy (15;16). Citalopram and escitalopram should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored (15;16). (7;21). Early clinical trials with sertraline suggested that seizures occurred at a similar frequency to placebo and only in people with a history of seizures (14). The seizure frequency in 100 (adult and paediatric) patients with epilepsy after being started on sertraline (mean dose 108mg) was assessed in one study (30). The mean treatment duration was 10.3 months (median duration 6 months, range 0.2 to 38 months). Six patients experienced an increase in seizure frequency but this could be definitely linked with sertraline in only one patient; sertraline was stopped in this patient. There was probable causality between seizure increase and sertraline in the other five patients; AED doses were adjusted and four continued with sertraline treatment. Reviews suggest sertraline has a seizure incidence of less than 0.1% at therapeutic doses of 50-100mg (31). Sertraline may interact with phenytoin due to reduced sertraline levels and potential inhibition of phenytoin metabolism. It can be considered as one of the first line options but as with all SSRI’s, itshould be used with caution in PWE (20;22). Serotonin / Noradrenaline Reuptake Inhibitors (SNRIs) An SNRI can be used as an alternative to an SSRI (9) but clinical experience and data regarding the safety of duloxetine in PWE is very limited and for both duloxetine and venlafaxine caution is required (7). Available through NICE Evidence Search at www.evidence.nhs.uk 3 Medicines Q&As A seizure rate of 0.2% with duloxetine therapy was reported in clinical trials (n=2418) (13). There is limited data and experience with duloxetine , therefore it (7) should still be used with caution in patients with a history or diagnosis of seizures (32). Cases of convulsions have been reported on discontinuation of therapy (32). Seizures have been reported in 0.3% of depressed patients (n=3082) treated with venlafaxine ≤150mg/day in clinical trials (13). In a large cohort study using data from primary care databases, venlafaxine was associated with a higher risk of epilepsy and seizures compared to other antidepressants, but as patients with a previous diagnosis of epilepsy/seizures were excluded, the results are not directly applicable to the scenario in this Q&A (33). Venlafaxine is also considered to increase seizure risk in overdose (7;34). If venlafaxine is prescribed, it should be introduced slowly in patients with a history of seizures; no interactions with antiepileptics is anticipated (14;34). Tricyclic Antidepressants (TCAs) All TCAs appear to lower the seizure threshold, with amitriptyline reputed to be the most proconvulsive and doxepin possibly of lowest risk (14). Ideally they should not be used in PWE (7). The overall incidence of seizures at therapeutic doses of TCAs is estimated at 0.4 to 1-2% (13), though the incidence for individual TCAs varies markedly (see Appendix 1). TCAs are also more likely to cause seizures in overdose compared with SSRIs (13). Most TCAs are known to potentially interact with anticonvulsants and manufacturer’s advice should be consulted for individual TCAs. Monamine Oxidase Inhibitors (MAOIs) MAOIs (phenelzine, isocarboxazid and tranylcypromine) have a low seizure risk but they are seldom used now due to their interactions with certain foods and drugs and the fact that there are safer alternatives available. However, they should be used with caution in PWE(35) and can increase or decrease seizure frequency (14). Moclobemide is a reversible inhibitor of monoamine oxidase type A (RIMA) which is less likely to interact with foods and drugs, and there have been no reports of problems in epilepsy to date (7;14;35). It is therefore considered a good choice in PWE and is not cautioned or contraindicated in these patients (7;36). Miscellaneous Antidepressants Rare cases of seizures with reboxetine (a noradrenaline reuptake inhibitor) have been reported in clinical studies but it has been tested in few patients with epilepsy; therefore it should be used with care in PWE (7;37). One study showed reboxetine (mean dose 6.9mg) to be an effective treatment without causing an increase in seizure frequency in 15 patients with temporal lobe epilepsy, when used for up to 30 weeks (29). Premarketing clinical trials suggest a seizure rate of 0.2% (13). Reboxetine is primarily metabolised by CYP3A4 and enzyme inducers such as phenobarbitone, carbamazepine and phenytoin, may reduce reboxetine plasma levels (37). There is limited data and experience with the newer antidepressant vortioxetine (serotonergic receptor modulator and serotonin re-uptake inhibitor), therefore it should be used with caution in patients with a history of seizures or unstable epilepsy (7;38). Vortioxetine is metabolised by CYP450, and enzyme inducers such as carbamazepine and phenytoin, may reduce vortioxetine plasma levels (38). Mirtazapine (a centrally active presynaptic alpha-2 antagonist) is associated with a minimal incidence of seizures of less than 0.1% with a 30mg dose suggested (39). However, one grand mal seizure has been reported in a patient with a history of seizures receiving mirtazapine at a dose of 80mg/day during a trial (14;40) (maximum licensed dose in UK is 45mg/day (41)). A second patient, with no history of seizures, developed generalised tonic-clonic seizures following initiation of mirtazapine 15mg/day, which stopped spontaneously (42). One study however showed mirtazapine (mean dose 32mg) to be an effective treatment without causing an increase in seizure frequency in 27 patients with temporal lobe epilepsy, when used for up to 30 weeks (29). In another small study, mirtazapine 30mg/day for 3 weeks was found to enhance cortical excitability in seven patients with epilepsy, but there was no increase in seizure frequency, duration or severity. The small numbers and short Available through NICE Evidence Search at www.evidence.nhs.uk 4 Medicines Q&As duration of the study limit the power of the study in this respect (43). Although clinical experience indicates that seizures are rare during mirtazapine therapy and it is considered a good choice in epilepsy (7), the manufacturers still advise caution (41). In addition, there is a significant interaction with carbamazepine and phenytoin (CPYP3A4 inducers), resulting in large reductions in mirtazapine plasma concentrations of 60% and 45% respectively; in such cases the mirtazapine dose may need to be increased (41). Agomelatine (a melatonergic agonist and 5-HT antagonist) appears to have no cautions or contraindications with regards to use in epilepsy (44) but there are very limited data regarding its safety in PWE (7). Other factors to consider Drug Interactions Some antidepressants may interact with anticonvulsants; this potential for interactions would need to be considered when choosing a suitable antidepressant agent for the patient. Plasma concentrations of the anticonvulsants should be carefully monitored if appropriate, particularly during the early phase of treatment with the antidepressant and doses adjusted accordingly (7). NICE recommends that generally SSRIs should be first-line treatment for depression in people with a chronic physical health problem and of the SSRIs, sertraline and citalopram probably have the lowest interaction potential (45). Dose initiation As a general rule, the more sedating a drug is, the more likely it is to induce seizures (7). There is a dose dependent relationship between antidepressant use and seizures. Patients should be commenced on a low dose, and this should be increased slowly until a therapeutic dose has been achieved, to reduce the risk of seizures (7). In addition, maximum recommended doses of antidepressants should not be exceeded. Limitations In general, very little specific information is available about the use of antidepressants in PWE. The SSRIs are the most widely studied antidepressants in PWE. Seizure rates quoted are often based on the incidence in patients with depression rather than PWE who suffer from depression, and this latter figure would be expected to be higher. Most studies investigating the relationship between antidepressants and seizure activity have examined the effects of antidepressants in overdose in the general population, making it difficult to extrapolate the findings to PWE. Seizure frequency often fluctuates and can increase as a result of various clinical conditions, such as fatigue or non-compliance with AEDs, and it is sometimes difficult to attribute the observed aggravation of seizures only to antidepressants in the absence of controls (12). Many of the early estimates of seizure incidence were based on case reports where there were many influencing variables and poor definitions for what constituted a convulsive event. Patients were also often taking concomitant medication, which may have affected seizure threshold, or, through inhibition of antidepressant metabolism, caused higher antidepressant plasma levels. Newer antidepressants have undergone clinical trials with improved methodology and with systematic reporting of adverse events. However, even these do not allow accurate comparisons to be made between the antidepressants. There is no large study comparing seizure frequency in PWE who take antidepressants with those who do not (12). Unless a large-scale trial is conducted, which is unlikely, the best antidepressant in epilepsy will remain unknown. Detailed information regarding drug interactions has not been included in this Q&A: pharmacokinetic and pharmacodynamic drug interactions between antidepressants and antiepileptic drugs must be checked prior to prescribing. References (1) Ojong M, Allen SN. Treatment of depression in patients with epilepsy. U S Pharmacist 2012; 37(11):29-32. Available through NICE Evidence Search at www.evidence.nhs.uk 5 Medicines Q&As (2) Cardamone L, Salzberg MR, O'Brien TJ et al. Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol 2013; 168:1531-1554. (3) Muzerengi S, Moor CC. What do we know about depression in people with epilepsy? Prog Neurol Psychiatry 2013; March/April:20-24. (4) Diagnosis and management of epilepsy in adults. Guideline No. 143. Updated May 2015. SIGN. Accessed via: http://www.sign.ac.uk/pdf/SIGN143.pdf on 05/12/2016. (5) Kondziella D, Asztely F. Don't be afraid to treat depression in patients with epilepsy! Acta Neurol Scand 2009; 119:75-80. (6) Yang Y, Gao X, Xu Y. The dilemma of treatments for epileptic patients with depression. International Journal of Neuroscience 2015; 125(8):566-577. (7) Taylor D, Paton C, Kapur S. Chapter 7: Use of psychotropic drugs in special patient groups. The Maudsley Prescribing Guidelines in Psychiatry. Twelfth edition. Oxford: Wiley-Blackwell, 2015: 632-635. (8) Noe HK, Locke DEC, Sirven JI. Treatment of depression in patients with epilepsy. Curr Treat Opt Neurol 2011; 13:371-379. (9) Barry JJ, Ettinger AB, Friel P et al. Consensus Statement: The evaluation and treatment of people with epilepsy and affective disorders. Epilepsy and Behaviour 2008; 13:S1-S29. (10) Mazza M, Marca GD, Di Nicola M et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy and Behaviour 2007; 10:397-401. (11) Antidepressants for people with epilepsy and depression (Review). Cochrane Database of Systematic Reviews. 2014. Accessed via: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010682.pub2/full on 16/11/2016. (12) Okazaki M, Adachi N, Ito M et al. One-year seizure prognosis in epilepsy patients treated with antidepressants. Epilepsy and Behaviour 2011; 22:331-335. (13) Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005; 59(12):1435-1440. (14) Bazire S. Chapter 3.4. Epilepsy. Section 3.4.2: Antidepressants. Pyschotropic Drug Directory 2016. Lloyd-Reinhold Communications LLP, 2016: 267. (15) Summary of Product Characteristics. Cipralex 5, 10 and 20mg film-coated tablets. Date of revision of the text: 05/09/2013. Lundbeck Limited. Accessed via: http://www.medicines.org.uk on 16/11/16. (16) Summary of Product Characteristics. Cipramil tablets. Date of revision of the text: 29/07/15. Lundbeck Limited. Accessed via: http://www.medicines.org.uk on 16/11/16. (17) Summary of Product Characteristics. Prozac 20mg hard capsules, and 20mg per 5ml oral liquid. Date of revision of the text: 08/02/2016. Eli Lilly and Company Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (18) Summary of Product Characteristics. Faverin 50mg film-coated tablets. Date of revision of the text: 31/08/2016. BGP Products Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. Available through NICE Evidence Search at www.evidence.nhs.uk 6 Medicines Q&As (19) Summary of Product Characteristics. Seroxat 10mg, 20mg, 30mg tablets, 20mg/10ml oral suspension. Date of revision of the text: 23/10/2015. GlaxoSmithKline UK. Accessed via: http://www.medicines.org.uk on 16/11/2016. (20) Summary of Product Characteristics. Lustral 50mg film coated tablets. Date of revision of the text: 11/2015. Pfizer Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (21) Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. J Neuropsychiatry Clin Neurosci 2005; 17(1):20-28. (22) Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. Br Med J 2014; 348:g2546. (23) Anon. Prompt diagnosis and treatment of depression in patients with epilepsy essential for patient well-being. Drugs and Therapy Perspectives 2003; 19(1):7-10. (24) Harmant J, van Rijckevorsel-Harmant K, de Barsy TH. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet 1990; 336(8711):386. (25) Kranthi K, Sathya Narayanan V, Jamuna Rani R et al. An interesting case of drug induced myoclonus in an epileptic patient. Ind J Pharmacol 2013; 45(Suppl 1):S225. (26) Wood DM, Rajalingham Y, Greene SL et al. Status epilepticus following intentional overdose of fluvoxamine: A case report with serum fluvoxamine concentration. Clin Toxicol 2007; 45:791-793. (27) Specchio LM, Iudice A, Specchio N et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004; 27(3):133-136. (28) Hovorka J, Herman E, Nemcová I. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behaviour 2000; 1:444-447. (29) Kühn K-U, Quednow BB, Thiel M et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behaviour 2003; 4:674-679. (30) Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy and Behaviour 2000; 1:100-105. (31) Mula M. The pharmacological management of psychiatric comorbidities in patients with epilepsy. Pharmacological Research 2016; 107:147-153. (32) Summary of Product Characteristics. Cymbalta 30mg hard gastro-resistant capsules, Cymbalta 60mg hard gastro-resistant capsules. Date of revision of the text: 01/01/2016. Eli Lilly and Company Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (33) Hill T, Coupland C, Morriss R et al. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry 2015; 15:315. (34) Summary of Product Characteristics. Efexor XL 75mg hard prolonged release capsules. Date of revision of the text: 20/10/2015. Pfizer Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (35) Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press <http://www.medicinescomplete.com> [Accessed on 16/11/2016] (36) Summary of Product Characteristics. Manerix 150mg. Date of revision of the text: 5/2016. Meda Pharmaceticals. Accessed via: http://www.medicines.org.uk on 16/11/2016. Available through NICE Evidence Search at www.evidence.nhs.uk 7 Medicines Q&As (37) Summary of Product Characteristics. Edronax 4mg tablets. Date of revision of the text: 10/2015. Pfizer Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (38) Summary of Product Characteristics. Brintellix tablest 5, 10 and 20mg. Date of revision of text: 17/06/2015. Lundbeck Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (39) Mula M, Schmitz B, Sander JW. The pharmacological treatment of depression in adults with epilepsy. Expert Opinion in Pharmacotherapy 2008; 9(18):3159-3168. (40) Bazire S. Chapter 3.4. Epilepsy. Section 3.4.2: Antidepressants. Pyschotropic Drug Directory 2014. Lloyd-Reinhold Communications LLP, 2014: 267. (41) Summary of Product Characteristics. Zispin SolTab 15mg, 30mg and 45mg orodispersible tablets. Date of revision of the text: 07/05/2015. Merck Sharp & Dohme Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (42) Teo L. Seizures associated with mirtazapine: A case report and review of literature. Conference Abstract, P-1116. European Psychiatry 2012; 27(Suppl 1). (43) Münchau A, Langosch JM, Gerschlager W et al. Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. J Neurol Neurosurg Psych 2005; 76:527-533. (44) Summary of Product Characteristics. Valdoxan. Date of revision of the text: 11/2015. Les Laboratories Servier. Accessed via: http://www.medicines.org.uk on 16/11/2016. (45) Depression in adults with a chronic physical health problem: treatment and management. NICE Clinical Guideline no. 91. National Collaborating Centre for Mental Health. Accessed via: http://www.nice.org.uk/guidance/CG91 on 07/11/2016. (46) Summary of Product Characteristics. Amitriptyline tablets BP 50mg. Date of revision of the text: 11/8/2016. Actavis UK Ltd. Accessed via: http://www.medicines.org.uk on 16//11/2016. (47) Summary of Product Characteristics. Clomipramine 50mg capsules, hard. Date of revision of the text: 16/06/2016. Generics [UK] Ltd t/a Mylan. (48) Summary of Product Characteristics. Prothiaden Capsules 25mg. Date of revision of the text: 05/07/2010. Teofarma S.r.L. Accessed via: http://www.mhra.gov.uk/spc-pil/ on 16/11/2016. (49) Summary of Product Characteristics. Sinepin capsules 25mg / Doxepin 25mg capsules. Date of revision of the text: 22/01/2014. Malborough Pharmaceuticals Ltd. Accessed via: http://www.medicines.org.uk on 16/11/2016. (50) Summary of Product Characteristics. Fluanxol tablets. Date of revision of the text: 13/05/2014. Lundbeck Limited. Accessed via: http://www.medicines.org.uk on 16/11/2016. (51) Summary of Product Characteristics. Imipramine tablets 10mg. Date of revision of the text: 24/03/2015. Actavis UK Ltd. Accessed via: http://www.medicines.org.uk on 16/11/2016. (52) Summary of Product Characteristics. Isocarboxazid tablets 10mg. Date of revision of the text: 14/01/2015. Alliance Pharmaceuticals. Accessed via: http://www.medicines.org.uk on 16/11/2016. (53) Summary of Product Characteristics. Lofepramine 70mg tablets. Date of revision of the text: 5/10/2015. Actavis UK Ltd. Accessed via: http://www.medicines.org.uk on 16/11/2016. Available through NICE Evidence Search at www.evidence.nhs.uk 8 Medicines Q&As (54) Summary of Product Characteristics. Mianserin 10mg tablets. Date of revision of the text:18/04/2012. Teva UK Limited. Accessed via: http://www.mhra.gov.uk/spc-pil/ on 16/11/2016. (55) Summary of Product Characteristics. Nortriptyline. Date of revision of the text: 11/09/2015. King Pharmaceuticals Ltd. Accessed via: http://www.medicines.org.uk on 16/11/2016. (56) Summary of Product Characteristics. Nardil tablets. Date of revision of the text: 10/2015. Kyowa Kirin Ltd. Accessed via: http://www.medicines.org.uk on 16/11/2016. (57) Summary of Product Characteristics. Tranylcypromine. Date of revision of the text: 28/10/2015. Concordia International. Accessed via: http://www.medicines.org.uk on 16/11/2016. (58) Summary of Product Characteristics. Molipaxin 50mg capsules. Date of revision of the text: 29/04/2015. Zentiva. Accessed via: http://www.medicines.org.uk on 16/11/2016. (59) Summary of Product Characteristics. Trimipramine 50mg capsules. Date of revision of the text: 09/06/2015. Zentiva. Accessed via: http://www.medicines.org.uk on 16/11/2016. Quality Assurance Prepared by Varinder Rai, Pharmacist, London Medicines Information Service (Northwick Park Hospital) Date Prepared November 2016 Checked by Georgina Glass, Pharmacist, London Medicines Information Service (Northwick Park Hospital) Date of check December 2016 Search strategy Embase: ((DEPRESSION/ AND EPILEPSY/) AND (CITALOPRAM/ OR ESCITALOPRAM/ OR FLUOXETINE/ OR PAROXETINE/ OR SERTRALINE/ OR VORTIOXETINE/ OR AMITRIPTYLINE/ OR CLOMIPRAMINE/ OR IMIPRAMINE/ OR LOFEPRAMINE/ OR TRIMIPRAMINE/ OR DOSULEPIN/ OR DOXEPIN/ OR MOCLOBEMIDE/ OR PHENELZINE/ OR TRANYLCYPROMINE/ OR NORTRIPTYLINE/ OR AGOMELATINE/ OR DULOXETINE/ OR FLUPENTIXOL/ OR FLUVOXAMINE/ OR ISOCARBOXAZIDE/ OR MIANSERIN/ OR MIRTAZAPINE/ OR REBOXETINE/ OR TRAZODONE/ OR VENLAFAXINE/)) [DT 2014-2016] [English language] [Humans] Embase: ((DEPRESSION/dt OR *"ANTIDEPRESSANT AGENT"/) AND*EPILEPSY/) [DT 2014-2016] [English language] [Humans] Medline: (CITALOPRAM/ OR FLUOXETINE/ OR FLUVOXAMINE/ OR PAROXETINE/ OR SERTRALINE/ OR TRAZODONE/ OR AMITRIPTYLINE/ OR CLOMIPRAMINE/ OR DOTHIEPIN/ OR IMIPRAMINE/ OR LOFEPRAMINE/ OR NORTRIPTYLINE/ OR TRIMIPRAMINE/ OR DOXEPIN/ OR "VENLAFAXINE HYDROCHLORIDE"/ OR "DULOXETINE HYDROCHLORIDE"/ OR (escitalopram).af OR FLUPENTHIXOL/ OR MIANSERIN/ OR ISOCARBOXAZID/ OR MOCLOBEMIDE/ OR PHENELZINE/ OR TRANYLCYPROMINE/ OR (mirtazapine).af OR (reboxetine).af OR (agomelatine).af OR (vortioxetine).af AND EPILEPSY/ Medline: (EPILEPSY/ AND DEPRESSION/dt) [DT 2014-2016] [Languages English] [Humans] Available through NICE Evidence Search at www.evidence.nhs.uk 9 Medicines Q&As Appendix 1: Manufacturers information [from Summaries of Product Characteristics] Drug Drug class* Special warnings for patients with epilepsy Adverse events: incidence of convulsions† Agomelatine (44) MRA/SSRA None Not reported Amitriptyline (46) TCA Reported, incidence not stated Citalopram (16) SSRI Avoid if possible. Avoid in unstable epilepsy. Monitor controlled epilepsy carefully. Discontinue if seizures occur or frequency increases. Clomipramine (47) TCA Use with extreme caution. Uncommon Dosulepin (48) TCA Avoid if possible. Rare Doxepin (49) TCA Use with caution. Unlikely Duloxetine (32) SNRI Use with caution. Rare Avoid in unstable epilepsy. Monitor controlled epilepsy carefully. Discontinue if seizures occur or frequency increases. Introduce with caution, discontinue if seizures occur or frequency increases. Avoid in unstable epilepsy. Monitor controlled epilepsy carefully. Use with caution. Avoid in unstable epilepsy. Monitor controlled epilepsy carefully. Discontinue if seizures occur or frequency increases. Rare (grand mal) Unknown (other convulsions) Escitalopram (15) SSRI Fluoxetine (17) SSRI Flupentixol (50) Neuroleptic Fluvoxamine (18) SSRI Imipramine (51) TCA Use with extreme caution. Rare Isocarboxazid (52) MAOI May increase or decrease seizures. Not reported Lofepramine (53) TCA Use with extreme caution. Rare Mianserin (54) TeCA Use with extreme caution. Reported. Incidence not stated Mirtazapine (41) AAA Use with caution: careful dosing and regular monitoring required. Unknown Moclobemide (36) RIMA None Not reported Nortriptyline (55) TCA Avoid if possible, if not, monitor carefully at the start of treatment. Reported, incidence not stated Paroxetine (19) SSRI Use with caution, discontinue if seizures occur. Rare Phenelzine (56) MAOI Use with great caution. Uncommon Use with caution. Monitor epilepsy, discontinue if seizures occur. Avoid in unstable epilepsy. Monitor controlled epilepsy carefully. Discontinue if seizures occur. Unknown Rare Reported, incidence not stated Rare Reboxetine (37) SNI Sertraline (20) SSRI Tranylcypromine (57) MAOI Use with great caution. Not reported Trazodone (58) Other Careful dosing and regular monitoring, avoid abrupt increases or decreases. Unknown Trimipramine (59) TCA Avoid if possible Rare Venlafaxine (34) SNRI Introduce with caution, convulsions may occur. Monitor epilepsy carefully. Discontinue if seizures occur. Rare Other Introduce with caution. Monitor and discontinue if seizures occur or frequency increases. Not reported Vortioxetine (38) Rare Uncommon Available through NICE Evidence Search at www.evidence.nhs.uk 10 Medicines Q&As * Drug class AAA: Alpha2 adrenoceptor antagonist RIMA: Reversible Inhibitor of Monoamine oxidase preferentially of type A MAOI: Monoamine Oxidase Inhibitor MRA/SSRA: Melatonin Receptor Agonist and Selective Serotonin Receptor Antagonist SNRI: Serotonin and Noradrenaline Reuptake Inhibitor SNI: Selective Noradrenaline reuptake Inhibitor SSRI: Selective Serotonin Reuptake Inhibitor TCA: Tricyclic Antidepressant TeCA: Tetracyclic Antidepressant †Incidence of adverse events Very common: ≥1/10 Common: ≥1/100 - <1/10 Uncommon: ≥1/1,000 - <1/100 Rare: ≥1/10,000 - <1/1,000 Unknown: adverse event has occurred but incidence cannot be estimated from available data Available through NICE Evidence Search at www.evidence.nhs.uk 11